Innoviva (INVA) EPS (Weighted Average and Diluted) (2010 - 2026)

Innoviva has reported EPS (Weighted Average and Diluted) for 16 years, with the latest figure at $2.22 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 400.0% year-over-year to $2.22; the trailing twelve-month figure through Mar 2026 stood at $3.33 (up 511.11% YoY), and the FY2025 full-year result was $3.3, up 816.67% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $2.22, up from $1.08 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $2.8 in Q3 2022, with the low at -$0.74 in Q1 2025.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.59 across 5 years, with a median of $0.42 in 2023.
• Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) slumped 2850.0% — and 2025, when it jumped 5300.0%.
• Innoviva's EPS (Weighted Average and Diluted) stood at $2.8 in 2022, then tumbled by 65.0% to $0.98 in 2023, then slumped by 97.96% to $0.02 in 2024, then jumped by 5300.0% to $1.08 in 2025, then jumped by 105.56% to $2.22 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $2.22 (Q1 2026), $1.08 (Q3 2025), and $0.77 (Q2 2025), per Business Quant data.